Vanguard Group Inc. Acquires 87,140 Shares of Teleflex Incorporated (NYSE:TFX)

Vanguard Group Inc. raised its holdings in Teleflex Incorporated (NYSE:TFX) by 1.8% in the 2nd quarter, HoldingsChannel reports. The firm owned 4,971,747 shares of the medical technology company’s stock after purchasing an additional 87,140 shares during the quarter. Vanguard Group Inc. owned 0.11% of Teleflex worth $1,646,394,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Reilly Financial Advisors LLC acquired a new position in Teleflex in the second quarter valued at about $25,000. Icon Wealth Partners LLC acquired a new position in Teleflex in the first quarter valued at about $37,000. Cullen Frost Bankers Inc. acquired a new position in Teleflex in the second quarter valued at about $52,000. FTB Advisors Inc. acquired a new position in Teleflex in the second quarter valued at about $54,000. Finally, Commonwealth Bank of Australia grew its stake in Teleflex by 347.4% in the second quarter. Commonwealth Bank of Australia now owns 170 shares of the medical technology company’s stock valued at $54,000 after acquiring an additional 132 shares during the period. Hedge funds and other institutional investors own 90.40% of the company’s stock.

In related news, Director Benson Smith sold 8,500 shares of the stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $331.90, for a total transaction of $2,821,150.00. Following the sale, the director now owns 85,300 shares of the company’s stock, valued at $28,311,070. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $332.17, for a total value of $66,434.00. Following the sale, the director now directly owns 936 shares in the company, valued at approximately $310,911.12. The disclosure for this sale can be found here. Insiders sold 34,604 shares of company stock worth $11,750,707 in the last 90 days. Corporate insiders own 2.36% of the company’s stock.



TFX has been the subject of several recent research reports. ValuEngine cut Teleflex from a “buy” rating to a “hold” rating in a research report on Tuesday, September 10th. Svb Leerink upped their price objective on Teleflex from $395.00 to $405.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 4th. Morgan Stanley upped their price objective on Teleflex from $345.00 to $392.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. JMP Securities upped their price objective on Teleflex from $325.00 to $395.00 and gave the stock a “market outperform” rating in a research report on Monday, August 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $403.00 price objective (up from $325.00) on shares of Teleflex in a research report on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $374.45.

TFX traded up $2.10 on Friday, hitting $343.80. 518,714 shares of the company were exchanged, compared to its average volume of 249,100. Teleflex Incorporated has a 12 month low of $226.02 and a 12 month high of $373.90. The company has a market cap of $15.76 billion, a PE ratio of 34.73, a PEG ratio of 2.21 and a beta of 1.00. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.59 and a current ratio of 2.52. The stock’s fifty day moving average is $357.46 and its 200-day moving average is $320.67.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, August 1st. The medical technology company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.07. Teleflex had a return on equity of 18.57% and a net margin of 10.78%. The business had revenue of $652.50 million for the quarter, compared to analyst estimates of $637.06 million. During the same quarter in the prior year, the company posted $2.47 earnings per share. Teleflex’s revenue was up 7.0% on a year-over-year basis. As a group, equities research analysts expect that Teleflex Incorporated will post 11.03 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Shareholders of record on Thursday, August 15th were paid a $0.34 dividend. The ex-dividend date was Wednesday, August 14th. This represents a $1.36 annualized dividend and a yield of 0.40%. Teleflex’s dividend payout ratio is 13.74%.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Featured Article: How To Calculate Debt-to-Equity Ratio

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.